Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Hecquet

Showing results (51-60 of 85) with videos related to

Pageof 9
Sort By:
European Journal of Cancer & Clinical Oncology|November 1, 1984
Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancerJ P Peyrat, P Vennin, J Bonneterre, et al.
Blood|November 1, 1994
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignanciesE Wattel, C Preudhomme, B Hecquet, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Type I insulin-like growth factor receptors in human colorectal cancerA Adenis, J P Peyrat, B Hecquet, et al.
Head & Neck|September 1, 1995
Epilarynx: pharynx or larynx?J L Lefebvre, E Buisset, B Coche-Dequeant, et al.
Cancer Research|June 15, 1989
Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in miceN A Boughattas, F Lévi, C Fournier, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatinB Hecquet, P Vennin, C Fournier, et al.
Bulletin Du Cancer|January 1, 1989
[48-hour continuous infusion of vindesine (followed by cisplatin) in advanced lung cancer. Chronopharmacokinetic data and clinical efficacy]C Focan, L Doalto, V Mazy, et al.
Toxicology and Applied Pharmacology|April 1, 1997
Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in miceX M Li, G Metzger, E Filipski, et al.
Biopharmaceutics & Drug Disposition|December 1, 1994
Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing timeN A Boughattas, B Hecquet, C Fournier, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1990
Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in miceN A Boughattas, F Lévi, C Fournier, et al.
Pageof 9

Showing results (51-60 of 85) with videos related to

Sort By:
Pageof 9
European Journal of Cancer & Clinical Oncology|November 1, 1984
Effect of bromocriptin treatment on prolactin and steroid receptor levels in human breast cancerJ P Peyrat, P Vennin, J Bonneterre, et al.
Blood|November 1, 1994
p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignanciesE Wattel, C Preudhomme, B Hecquet, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1995
Type I insulin-like growth factor receptors in human colorectal cancerA Adenis, J P Peyrat, B Hecquet, et al.
Head & Neck|September 1, 1995
Epilarynx: pharynx or larynx?J L Lefebvre, E Buisset, B Coche-Dequeant, et al.
Cancer Research|June 15, 1989
Circadian rhythm in toxicities and tissue uptake of 1,2-diamminocyclohexane(trans-1)oxalatoplatinum(II) in miceN A Boughattas, F Lévi, C Fournier, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1985
Platinum concentration in human tumors of head and neck, uterine cervix, and breast following treatment with cisplatinB Hecquet, P Vennin, C Fournier, et al.
Bulletin Du Cancer|January 1, 1989
[48-hour continuous infusion of vindesine (followed by cisplatin) in advanced lung cancer. Chronopharmacokinetic data and clinical efficacy]C Focan, L Doalto, V Mazy, et al.
Toxicology and Applied Pharmacology|April 1, 1997
Pharmacologic modulation of reduced glutathione circadian rhythms with buthionine sulfoximine: relationship with cisplatin toxicity in miceX M Li, G Metzger, E Filipski, et al.
Biopharmaceutics & Drug Disposition|December 1, 1994
Comparative pharmacokinetics of oxaliplatin (L-OHP) and carboplatin (CBDCA) in mice with reference to circadian dosing timeN A Boughattas, B Hecquet, C Fournier, et al.
The Journal of Pharmacology and Experimental Therapeutics|November 1, 1990
Stable circadian mechanisms of toxicity of two platinum analogs (cisplatin and carboplatin) despite repeated dosages in miceN A Boughattas, F Lévi, C Fournier, et al.
Pageof 9